File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study

TitleAutologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study
Authors
Issue Date2008
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/bbmt
Citation
Biology Of Blood And Marrow Transplantation, 2008, v. 14 n. 12, p. 1356-1364 How to Cite?
AbstractExtranodal natural killer (NK)/T cell lymphoma, nasal type, is a recently recognized distinct entity and the most common type of non-B cell extranodal lymphoma in Asia. This retrospective analysis studied the potential survival benefits of hematopoeitic stem cell transplantation (HSCT) compared with a historical control group. A total of 47 patients from 3 previously published series of HSCT were matched according to NK/T cell lymphoma International Prognostic Index (NKIPI) risk groups and disease status at transplantation with 107 patients from a historical control group for analysis. After a median follow-up of 116.5 months, the median survival time was not determined for the HSCT group, but it was 43.5 months for the control group (95% confidence interval [CI] = 6.7 to 80.3 months; P = .127, log-rank test). In patients who were in complete remission (CR) at the time of HSCT or at surveillance after remission, disease-specific survival rates were significantly higher in the HSCT group compared with the control group (disease-specific 5-year survival rate, 87.3% for HSCT vs 67.8% for non-HSCT; P = .027). In contrast, in subgroup analysis on non-CR patients at the time of HSCT or non-HSCT treatment, disease-specific survival rates were not significantly prolonged in the HSCT group compared with the control group (1-year survival rate, 66.7% for HSCT vs 28.6% for non-HSCT; P = .141). The impact of HSCT on the survival of all patients was significantly retained at the multivariate level with a 2.1-fold (95% CI =1.2- to 3.7-fold) reduced risk of death (P = .006). HSCT seems to confer a survival benefit in patients who attained CR on postremission consolidation therapy. These findings suggest that, in particular, patients in CR with high NKIPI risk scores at diagnosis should receive full consideration for HSCT. © 2008 American Society for Blood and Marrow Transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/59369
ISSN
2015 Impact Factor: 3.98
2015 SCImago Journal Rankings: 2.094
ISI Accession Number ID
Funding AgencyGrant Number
Samsung Medical CenterOTX1070211
Funding Information:

This study was supported by Samsung Medical Center grant OTX1070211.

References

 

DC FieldValueLanguage
dc.contributor.authorLee, Jen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorPark, MJen_HK
dc.contributor.authorSuzumiya, Jen_HK
dc.contributor.authorNakamura, Sen_HK
dc.contributor.authorKameoka, JIen_HK
dc.contributor.authorSakai, Cen_HK
dc.contributor.authorOshimi, Ken_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorYiu, Hen_HK
dc.contributor.authorWong, KHen_HK
dc.contributor.authorCheng, HCen_HK
dc.contributor.authorRyoo, BYen_HK
dc.contributor.authorSuh, Cen_HK
dc.contributor.authorKo, YHen_HK
dc.contributor.authorKim, Ken_HK
dc.contributor.authorLee, JWen_HK
dc.contributor.authorKim, WSen_HK
dc.contributor.authorSuzuki, Ren_HK
dc.date.accessioned2010-05-31T03:48:35Z-
dc.date.available2010-05-31T03:48:35Z-
dc.date.issued2008en_HK
dc.identifier.citationBiology Of Blood And Marrow Transplantation, 2008, v. 14 n. 12, p. 1356-1364en_HK
dc.identifier.issn1083-8791en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59369-
dc.description.abstractExtranodal natural killer (NK)/T cell lymphoma, nasal type, is a recently recognized distinct entity and the most common type of non-B cell extranodal lymphoma in Asia. This retrospective analysis studied the potential survival benefits of hematopoeitic stem cell transplantation (HSCT) compared with a historical control group. A total of 47 patients from 3 previously published series of HSCT were matched according to NK/T cell lymphoma International Prognostic Index (NKIPI) risk groups and disease status at transplantation with 107 patients from a historical control group for analysis. After a median follow-up of 116.5 months, the median survival time was not determined for the HSCT group, but it was 43.5 months for the control group (95% confidence interval [CI] = 6.7 to 80.3 months; P = .127, log-rank test). In patients who were in complete remission (CR) at the time of HSCT or at surveillance after remission, disease-specific survival rates were significantly higher in the HSCT group compared with the control group (disease-specific 5-year survival rate, 87.3% for HSCT vs 67.8% for non-HSCT; P = .027). In contrast, in subgroup analysis on non-CR patients at the time of HSCT or non-HSCT treatment, disease-specific survival rates were not significantly prolonged in the HSCT group compared with the control group (1-year survival rate, 66.7% for HSCT vs 28.6% for non-HSCT; P = .141). The impact of HSCT on the survival of all patients was significantly retained at the multivariate level with a 2.1-fold (95% CI =1.2- to 3.7-fold) reduced risk of death (P = .006). HSCT seems to confer a survival benefit in patients who attained CR on postremission consolidation therapy. These findings suggest that, in particular, patients in CR with high NKIPI risk scores at diagnosis should receive full consideration for HSCT. © 2008 American Society for Blood and Marrow Transplantation.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/bbmten_HK
dc.relation.ispartofBiology of Blood and Marrow Transplantationen_HK
dc.rightsBiology of Blood and Marrow Transplantation. Copyright © Elsevier Inc.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAgeden_HK
dc.subject.meshCase-Control Studiesen_HK
dc.subject.meshDisease-Free Survivalen_HK
dc.subject.meshFar Easten_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHematopoietic Stem Cell Transplantationen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLymphoma, Extranodal NK-T-Cell - diagnosis - mortality - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshRisk Factorsen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshTransplantation, Autologousen_HK
dc.titleAutologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1083-8791&volume=14&issue=12&spage=1356&epage=1364 &date=2008&atitle=Autologous+Hematopoietic+Stem+Cell+Transplantation+in+Extranodal+Natural+Killer/T+Cell+Lymphoma:+A+Multinational,+Multicenter,+Matched+Controlled+Study+en_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.bbmt.2008.09.014en_HK
dc.identifier.pmid19041057-
dc.identifier.scopuseid_2-s2.0-56549093825en_HK
dc.identifier.hkuros160116en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-56549093825&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue12en_HK
dc.identifier.spage1356en_HK
dc.identifier.epage1364en_HK
dc.identifier.isiWOS:000261754600005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLee, J=8601862700en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridPark, MJ=8428794400en_HK
dc.identifier.scopusauthoridSuzumiya, J=7005666128en_HK
dc.identifier.scopusauthoridNakamura, S=35323670300en_HK
dc.identifier.scopusauthoridKameoka, JI=7004592976en_HK
dc.identifier.scopusauthoridSakai, C=7005606065en_HK
dc.identifier.scopusauthoridOshimi, K=7006673135en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridYiu, H=6603694447en_HK
dc.identifier.scopusauthoridWong, KH=7404760106en_HK
dc.identifier.scopusauthoridCheng, HC=7404285241en_HK
dc.identifier.scopusauthoridRyoo, BY=6603026326en_HK
dc.identifier.scopusauthoridSuh, C=7102970953en_HK
dc.identifier.scopusauthoridKo, YH=16646069600en_HK
dc.identifier.scopusauthoridKim, K=36078427800en_HK
dc.identifier.scopusauthoridLee, JW=36068277200en_HK
dc.identifier.scopusauthoridKim, WS=34975082200en_HK
dc.identifier.scopusauthoridSuzuki, R=35381312500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats